116.99
2.01%
-2.40
After Hours:
116.99
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Abbott Laboratories stock is traded at $116.99, with a volume of 8.25M.
It is down -2.01% in the last 24 hours and up +2.89% over the past month.
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
See More
Previous Close:
$119.39
Open:
$118.89
24h Volume:
8.25M
Relative Volume:
1.55
Market Cap:
$203.59B
Revenue:
$41.22B
Net Income/Loss:
$5.77B
P/E Ratio:
39.79
EPS:
2.94
Net Cash Flow:
$5.65B
1W Performance:
-0.22%
1M Performance:
+2.89%
6M Performance:
+9.05%
1Y Performance:
+20.88%
Abbott Laboratories Stock (ABT) Company Profile
Name
Abbott Laboratories
Sector
Industry
Phone
(224) 667-6100
Address
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
Abbott Laboratories Stock (ABT) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Oct-08-24 | Initiated | Oppenheimer | Outperform |
Sep-19-24 | Initiated | Piper Sandler | Overweight |
Jul-30-24 | Downgrade | Edward Jones | Buy → Hold |
May-30-24 | Initiated | Goldman | Buy |
Jul-21-23 | Upgrade | Wolfe Research | Underperform → Peer Perform |
May-30-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
Apr-20-23 | Reiterated | Barclays | Overweight |
Apr-20-23 | Reiterated | Bernstein | Outperform |
Apr-20-23 | Reiterated | JP Morgan | Overweight |
Apr-20-23 | Reiterated | Raymond James | Outperform |
Apr-20-23 | Reiterated | UBS | Buy |
Apr-20-23 | Reiterated | Wolfe Research | Underperform |
Mar-29-23 | Initiated | UBS | Buy |
Oct-26-22 | Initiated | Mizuho | Neutral |
Oct-18-22 | Initiated | Barclays | Overweight |
Oct-12-22 | Initiated | Jefferies | Hold |
Jul-06-22 | Initiated | Wolfe Research | Underperform |
Mar-02-22 | Resumed | BofA Securities | Buy |
Jan-27-22 | Reiterated | Credit Suisse | Outperform |
Jan-27-22 | Reiterated | Morgan Stanley | Overweight |
Jan-27-22 | Reiterated | Raymond James | Outperform |
Jan-27-22 | Reiterated | UBS | Buy |
Dec-10-21 | Initiated | RBC Capital Mkts | Outperform |
Oct-27-21 | Upgrade | Atlantic Equities | Neutral → Overweight |
Oct-14-21 | Initiated | Redburn | Neutral |
May-25-21 | Initiated | Barclays | Overweight |
Apr-15-21 | Initiated | Atlantic Equities | Neutral |
Jan-28-21 | Upgrade | BTIG Research | Neutral → Buy |
Sep-11-20 | Initiated | Wolfe Research | Outperform |
Jun-01-20 | Downgrade | Goldman | Neutral → Sell |
Mar-05-20 | Initiated | Citigroup | Buy |
Feb-13-20 | Initiated | Goldman | Neutral |
Feb-06-20 | Resumed | BTIG Research | Neutral |
Jan-02-20 | Downgrade | Guggenheim | Buy → Neutral |
Jun-13-19 | Reiterated | BofA/Merrill | Buy |
Feb-07-19 | Reiterated | BofA/Merrill | Buy |
Jan-02-19 | Downgrade | Citigroup | Neutral → Sell |
Nov-30-18 | Upgrade | Goldman | Neutral → Buy |
Oct-16-18 | Initiated | Barclays | Overweight |
Jun-27-18 | Initiated | Bernstein | Outperform |
Jan-30-18 | Reiterated | Citigroup | Neutral |
Jan-25-18 | Reiterated | Stifel | Buy |
Jan-25-18 | Upgrade | William Blair | Mkt Perform → Outperform |
Jan-03-18 | Initiated | Evercore ISI | Outperform |
Jan-02-18 | Upgrade | JP Morgan | Neutral → Overweight |
Jan-02-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
Oct-19-17 | Reiterated | RBC Capital Mkts | Outperform |
Oct-19-17 | Reiterated | Stifel | Buy |
View All
Abbott Laboratories Stock (ABT) Latest News
Abbott Laboratories Employees Credit Union Data Breach Caused by Compromised Email Account - JD Supra
Abbott Laboratories stock underperforms Monday when compared to competitors - MarketWatch
Abbott Laboratories (NYSE:ABT) Trading Down 1.7%Here's Why - MarketBeat
Christine Poole's Past Picks: ABBOTT LABS, JPMORGAN CHASE, and Thermo Fisher Scientific - BNN Bloomberg
Penn Davis Mcfarland Inc. Makes New $3.62 Million Investment in Abbott Laboratories (NYSE:ABT) - MarketBeat
Abbott Laboratories: Long-Term Optimism, Short-Term Overvaluation (NYSE:ABT) - Seeking Alpha
Vest Financial LLC Acquires 53,887 Shares of Abbott Laboratories (NYSE:ABT) - MarketBeat
Stratos Wealth Partners LTD. Has $13.38 Million Holdings in Abbott Laboratories (NYSE:ABT) - MarketBeat
Abbott Laboratories stock outperforms competitors on strong trading day - MarketWatch
Abbott Laboratories (ABT): Strong Q2 Performance and Innovative Product Approvals - Insider Monkey
Abbott Laboratories (NYSE:ABT) Stock Price Up 0.6% After Analyst Upgrade - MarketBeat
Wall Street Analysts Think Abbott (ABT) Is a Good Investment: Is It? - Yahoo Finance
Where Will DexCom Be in 5 Years? - The Motley Fool
Abbott Laboratories Third Quarter 2024 Earnings: EPS Beats Expectations - Simply Wall St
Buffington Mohr McNeal Has $8.37 Million Stock Position in Abbott Laboratories (NYSE:ABT) - MarketBeat
Abbott reports sales of $10.6bn for Q3 2024 - Medical Device Network
These Analysts Increase Their Forecasts On Abbott Laboratories After Better-Than-Expected Q3 Earnings - MSN
Abbott Laboratories (NYSE:ABT) Shares Down 0.3%Should You Sell? - MarketBeat
Abbott Laboratories stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch
Abbott Labs Path To Double-Digit Earnings Growth In 2025? This Analyst Is Optimistic - Benzinga
Calls of the Day: Crowdstrike, Cheniere Energy, 3M, Abbott Labs, Abbvie and Eli Lilly - MSN
Abbott Lifts Annual Profit Forecast, Banks on CGM Sales - MD+DI
Oppenheimer maintains Outperform rating on Abbott Labs stock post-earnings By Investing.com - Investing.com UK
Morgan Stanley Raises Abbott Laboratories (NYSE:ABT) Price Target to $117.00 - MarketBeat
Abbott Laboratories (NYSE:ABT) Issues Quarterly Earnings Results - MarketBeat
Abbott Laboratories (NYSE:ABT) Q3 2024 Earnings Call Transcript - MSN
Is Abbott Laboratories Stock a Buy? - MSN
AbbVie Is Doing 'Very Well' But Jim Cramer's Favorite? Abbott Laboratories - Benzinga
Abbott stock boosted by medtech outperformance, says Piper Sandler - Investing.com
Searle denies interest in acquiring stake in Abbott Laboratories - Profit by Pakistan Today
Hematology Market Set to Witness Significant Growth by 2024-2031: Abbott Laboratories, Beckman Coulter, - EIN News
Abbott Laboratories Q3 Earnings Preview: Profit boost expected - MSN
Abbott: Q3 Earnings Snapshot - San Antonio Express-News
Abbott Laboratories (ABT) Q3 2024 Earnings Call Highlights: Strong Growth in Diabetes Care and ... - Yahoo Finance
Abbott Laboratories (ABT) Q3 2024 Earnings Call Highlights: Stro - GuruFocus.com
Why Abbott Laboratories Stock Was a Winner on Wednesday - sharewise
Cramer's Stop Trading: Abbott Labs - MSN
Abbott Laboratories Raises Its Outlook on Strong Medical Device Sales - MSN
Why Abbott Laboratories (ABT) Stock is Moving Today - GuruFocus.com
Jefferies lifts Abbott Labs target to $125 on solid Q3 sales - Investing.com
JPMorgan maintains $135 target on Abbott Labs amid strong growth - Investing.com
Abbott (ABT) Reports Mixed Q2 Financial Results with Revenue Gro - GuruFocus.com
Wintrust Business Minute: Abbott Laboratories to launch $7 billion stock buyback programWGN Radio - WGN Radio - Chicago
Abbott Labs Stock Rises As Medical Devices Drive Quarterly Beat - Investor's Business Daily
Stifel raises Abbott Labs target to $130 on growth outlook - Investing.com
Earnings call: abbott reports 8% organic sales growth, raises guidance - Investing.com
Abbott Labs target raised to $128 on confident growth outlook - Investing.com
Abbott Labs target raised to $128 on confident growth outlook By Investing.com - Investing.com UK
Committee Stocks on the Move: Interactive Brokers, Abbott Labs and Rio Tinto - CNBC
Abbott Labs Reports Strong Q3 Performance Despite Challenges - GuruFocus.com
BTIG raises Abbott Labs target on Q3 beat - Investing.com
Abbott Laboratories Stock (ABT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):